MARATTO

article · Natural Product Research

Phenolic and volatile constituents of <i>Halogeton sativus</i> (L.) moq., with anti-inflammatory, antioxidant, and photoprotective effects: a first report

Abstract

Characterising the chemical composition of <i>Halogeton sativus</i> (L.) Moq. essential oil and its AcOEt (HSAE) and <i>n</i>-BuOH (HSBE) fractions aimed to evaluate their anti-inflammatory, antioxidant, and photoprotective properties. The main volatile components were tetracosane (14.55%), pentacosane (18.09%), and hexahydrofarnesylacetone (46.45%). Key phenolic constituents included gentisic, salicylic, chlorogenic, caffeic, and <i>p</i>-coumaric acids, with quercetin being the predominant compound in HSAE (33.62 mg/g). Antioxidant tests (DPPH•, ABTS<sup>•+</sup>, FRAP, and phenanthroline) indicated that HSAE demonstrated higher capacity (IC<sub>50</sub> = 7.90 ± 0.15 μg/mL, IC<sub>50</sub> = 13.36 ± 0.01 μg/mL, A<sub>0.5</sub> = 16.14 ± 0.09 μg/mL, and A<sub>0.5</sub> = 16.14 ± 0.09 μg/mL, respectively). Both HSBE and HSAE exhibited photoprotective efficacy with an SPF value around 33.9. Their anti-inflammatory potential was significant, with IC<sub>50</sub> values of 35.16 ± 0.93 and 78.15 ± 0.13 µg/mL, respectively. These findings suggest the possible applications of <i>H. sativus</i> for reducing inflammation, oxidative stress, and UV damage protection.

Research topics

  • Plant chemical constituents analysis
  • Phytochemistry and Biological Activities
  • Plant Toxicity and Pharmacological Properties

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1080/14786419.2026.2649928

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.